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Introduction. 
Ropivacaine, S-(-)-1-propyl-2' 6' -pipecholoxy lidide hydrochloride monohydrate, is the 
latest in the series of amide local anaesthetic agents, the development of which has been 
spurred by the need for an agent that would be effective and long lasting but have 
minimal toxic effects. 
Bupivacaine has been the local anaesthetic of choice for many years but the serious, 
albeit rare, cardiac toxicity associated with its use has prompted research for a safer 
agent. The toxic effects of the long acting local anaesthetics were reported by Albright 
in 1979, in an editorial in Anesthesiology (1). He reported 6 cases of presumed 
accidental intravascular injection of either etidocaine or bupivacaine, which caused 
convulsions and ventricular arrhythmia. Three cases were attempted brachial plexus 
blockade with 0.5% bupivacaine, one was an intravenous regional anaesthetic with 
0.5% bupivacaine and chloroprocaine, one was a caudal extradural anaesthetic with 
etidocaine and one was an extradural block with 0.75% bupivacaine. 
Subsequently, sporadic cases of maternal death after extradural anaesthesia for 
Caesarean section were reported (2). In the UK there were 5 deaths after intravenous 
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regional anaesthesia administered by trainee casualty officers. Tourniquet malfunction 
and bupivacaine were involved in all of these cases (3) . 
In response to Albright's findings, the United States Food and Drug administration 
issued a statement that 0.75% bupivacaine was no longer recommended for obstetric 
anaesthesia. 
This adverse attention provided the impetus for the development of a local anaesthetic 
with the efficacy of bupivacaine but with lower toxicity. Ropivacaine has been 
developed as the drug with these required characteristics. 
The purpose of this thesis is to review the pharmacology and toxicity of local 
anaesthetics, particularly highlighting the differences between bupivacaine and 
ropivacaine and to present an experiment attempting to establish whether ropivacaine is 
a safer drug, once cardiotoxicity has occurred. 
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Mechanism of Action of Local Anaesthetics. 
Local anaesthetics are tertiary bases and are supplied as the hydrochloride to ensure 
water solubility for ease of administration. After administration, tissue buffering raises 
the pH and a percentage of the drug dissociates to become free base. The free base is 
lipid soluble and able to penetrate the nerve sheath and lipid cell membrane to enter the 
axoplasm where it partially re-ionises again. The ionised form then enters the sodium 
channel and prevents the flow of sodium ions into the cell. As a result, action potentials 
are neither generated nor propagated and conduction blockade has occurred. 
Sodium channels. 
The sodium channels are postulated to exist in 3 different forms ( 4). 
1. A resting state R, in which sodium activation and inactivation gates are closed and 
which predominates before nerve stimulation. 
2. An open state 0 , in which both gates are open, allowing passage of sodium ions 
during stimulation. This state is present during depolarisation of the membrane. 
3. An inactive state I, in which the activation gate remains open but the inactivation 
gate is closed immediately following stimulation. This state is associated with the 
initial phase of repolarisation and the refractory period. 
Local anaesthetics have a high affinity for channels in the open or inactivated states but 
a very low affinity for channels in the rested state. Consequently, in cardiac muscle, 
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block of sodium channels develops during the upstroke and plateau of the action 
potential and dissipates during the diastolic interval between beats (4). 
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Cardiotoxicity of Local Anaesthetic Agents. 
In order to understand the effects exerted on the heart by local anaesthetics, one must 
first understand normal cardiac electrophysiology. 
The resting membrane potential of cardiac muscle cells is about -90m V (interior 
negative to exterior). Stimulation produces a propagated action potential that is 
responsible for initiating contraction. Rapid depolarisation occurs followed by a plateau 
phase before the membrane potential returns to the baseline. The depolarisation lasts for 
about 2ms but the plateau phase and repolarisation last 200ms or more, so that 
repolarisation is not complete until the contraction is half over. Recorded 
extracellularly, the summed electrical activity of all the cardiac muscle fibres is the 
electrocardiogram. The electrical events include a spike and a later wave that resemble 
the QRS complex and T wave of the ECG. As in all excitable tissues, changes in the 
potassium ion concentration affect the resting membrane potential of cardiac muscle, 
whereas changes in the sodium ion concentration affect the magnitude of the action 
potential. The initial rapid depolarisation and the overshoot phase (phase ON max) are 
due to a rapid increase in sodium conductance similar to that occurring in nerve and 
skeletal muscle. The accumulated upstrokes of the ventricular action potentials account 
for the QRS complex on the ECG. The maximal rate ofrise (Vmax) is a major 
determinant of the conduction velocity and duration of the QRS complex on the ECG. 
The initial rapid repolarisation (phase 1) is due to closure of sodium channels and 
chloride influx. The subsequent prolonged plateau (phase 2) is due to a slower but 
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prolonged opening of voltage gated calcium channels. This plateau is reflected on the 
body surface ECG as the ST segment. 
Final repolarisation (phase 3) is due to closure of the calcium channels and potassium 
efflux through 2 types of potassium channels and is responsible for the T wave of the 
ECG. This restores the resting potential (phase 4). 
The fast sodium channel probably has 2 gates, an outer gate that opens at the start of 
depolarisation, at a membrane potential of -70 to -80m V, and a second inner gate that 
then closes and precludes further influx until the action potential is over (sodium 
channel inactivation). 
Local anaesthetics manifest their toxicity at a local and systemic level. Neurotoxicity 
has been attributed to antioxidants or preservative agents but it seems that local toxicity 
is related to the concentration of agent used (5). Muscles are also damaged by local 
anaesthetics ( 6), but it is the dramatic central nervous system and cardiac effects that 
are probably the most important side effects of these agents. 
Most of the work on local anaesthetic toxicity has involved comparisons between 
bupivacaine and other agents. 
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Studies on isolated myocardial tissue. 
Electrophysiological studies have shown that local anaesthetics depress the maximal 
rate of increase of the cardiac action potential (V max) in a dose dependent manner 
depending on membrane potential and rate of stimulation (7). Vmax is dependent on 
the sodium ion influx via sodium channels. Local anaesthetics depress the cardiac 
sodium channels in a time and a voltage manner by binding to specific sites within the 
sodium channel. Highly lipid soluble compounds reach their site of action throughout 
the membrane whereas the binding site is only accessible to polar compounds when the 
channel is open. Drug affinity for the receptor site is dependent on the state of the 
sodium channel with local anaesthetics having high affinity for the open or inactivated 
channel and low affinity for the resting channel. Inhibition of sodium channel by local 
anaesthetics includes both voltage dependant and frequency dependant components. 
The block is enhanced by rapid stimulation and depolarisation and dissipates with 
hyperpolarisation and increase in cycle length. Thus, changes in heart rate and diastolic 
membrane potential may alter drug action. 
Clarkson and Hondeghem (8) studied the effect of lignocaine and bupivacaine at 
various concentrations and stimulation rates on guinea pig ventricular muscle V max. In 
high concentrations, lignocaine blocked sodium channels in a fast in fast out manner. In 
low concentrations, bupivacaine blocked sodium channels in a slow in slow out 
manner, whereas in high concentrations the bupivacaine block was of a fast in slow out 
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type. Therefore recovery from bupivacaine induced block is always slow and the block 
can accumulate even at low heart rates, making bupivacaine a more potent depressor of 
Vmax than lignocaine. 
In the intact heart, reduction in V max which results in slowed conduction of the cardiac 
action potential, is manifested by prolongation of the PR interval and QRS complex (7). 
Slowed conduction may also result in re-entrant phenomena (9), which may account for 
the sudden onset of ventricular arrhythmia after toxic doses of bupivacaine. 
Dose dependant depression of cardiac conduction and contractility by local anaesthetics 
has been demonstrated in the isolated rabbit heart preparation (10). The effect of 
bupivacaine was apparent at a lower dose than that of lignocaine. 
Feldman et al investigated the effect of local anaesthetics on the chronotropy and 
inotropy of the isolated guinea pig atrium. They showed that the relative potency of the 
various agents in depressing cardiac contractility is similar to the anaesthetic potency of 
the drug (11) . 
Moller et al looked at the effect of bupivacaine and lignocaine on the action potential of 
the right bundle of the rabbit heart. They found that bupivacaine was a far more potent 
depressor of membrane potential, V max, action potential duration, and conduction 
time. The agents appeared to block the entrance of sodium through fast sodium 
channels (12) . 
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Calcium is important in the conduction of the action potential in the atrio-ventricular 
pathway especially the SA and AV nodes. Calcium influx initiates and controls the 
force of contraction in the process of excitation contraction coupling. Therefore the 
effect of local anaesthetics, especially bupivacaine, may be important in the 
pathophysiology of local anaesthetic toxicity. Arlock showed that bupivacaine causes 
attenuation and block of automaticity at potentials where calcium conductance is high. 
This may indicate that bupivacaine affects the transmembrane calcium current which is 
responsible for triggering the contractile apparatus (13). 
Coyle studied the effect of bupivacaine on calcium channels in the guinea pig heart. 
Blockade of sodium channels was achieved by perfusing the hearts with high levels of 
potassium. Pharmacological concentrations of bupivacaine depressed Vmax by 50% 
suggesting that bupivacaine inhibits the slow inward calcium current (14). 
The duration of the cardiac action potential is mainly controlled by potassium currents 
flowing through several different voltage dependent potassium channels. Prolongation 
of the action potential by potassium channel block may contribute to local anaesthetic 
toxicity because of an increased number of open or inactivated sodium channels. It has 
been shown that in dogs that are normally ventilated but hyperkalaemic, bupivacaine 
toxicity occurred at a lower dose than when the dogs were normokalaemic (15) . 
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Significant blockade of the delayed rectifier potassium current and the inward rectifier 
potassium current potassium channels in the frog heart, has been produced by 
bupivacaine in concentrations that cause sodium channel block (16). Castle showed that 
bupivacaine was a potent blocker of the delayed rectifier potassium current and the 
transient outward potassium channel. This results in prolongation of the action 
potentials as the duration of the action potential is controlled by potassium flow 
through several potassium channels. Prolongation of the action potential results in an 
increase in the time that the sodium channels spend in the inactivated state which is the 
state in which they are most vulnerable to the effect of bupivacaine 
In summary, the in vitro effect of local anaesthetic agents seems to be related to their 
affinity for and duration of binding to sodium channels. Bupivacaine also has an effect 
on calcium channels and potassium channels. 
Studies on intact animals. 
Liu has investigated the effect of an intravenous bolus of amide local anaesthetics 
administered to anaesthetised ventilated dogs (17). He found that bupivacaine caused 
profound hypotension compared to mild cardiac depression with the same dose of 
lignocaine and prilocaine. The cardiodepressant effect was proportional to their in vivo 
anaesthetic potency. Death occurred as a result of progressive cardiac depression and no 
arrhythmias were recorded. 
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Nath (18) infused bupivacaine and lignocaine into the left anterior descending artery in 
pigs in order to study the effect on the heart while eliminating any possible effects 
mediated by the central nervous system. He noted a dose dependant depression of the 
left ventricle in the ratio of anaesthetic potency. Bupivacaine was 4 times more potent 
than lignocaine in depressing contractility but 16 times more potent in prolonging the 
QRS interval. 50% of the animals given bupivacaine died of sudden ventricular 
fibrillation. 
Thigpen (19) studied sheep rendered acidotic and hypoxaemic by ventilation with a 
mixture of air and 12% carbon dioxide. 100% of these sheep died as a result of 
bupivacaine infusion. This was in contrast to a study by Kotelko (20) in which hypoxia 
was avoided during treatment with bupivacaine. All the animals developed serious 
arrhythmias but the mortality was very low. Kotelko postulated that under conditions of 
hypoxia and acidosis, bupivacaine toxicity is potentiated. 
Mets demonstrated in rats that respiratory depression occurs before serious cardiac 
depression due to bupivacaine toxicity (21). This was confirmed in a study by 
Nancarrow (22). 
Mallampati et al reported a case of bupivacaine toxicity in which successful 
resuscitation was achieved. This was attributed by them to early aggressive 
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cardiorespiratory support and they commented that there was mounting evidence that 
prevention of hypoxia was associated with a good outcome (23). 
In summary, at toxic concentrations, bupivacaine alters cardiac function by decreasing 
the myocardial contractile force, and creating dysrhythmias, high degree blocks, major 
QRS widening and ventricular tachycardias of the re-entrant type (24). 
A) Inotropy. 
Multiple studies both in vitro and in vivo have shown that bupivacaine has a strongly 
negative inotropic action (25,26,27,28). 
B) Electrophysiology. 
Depression of cardiac conduction is one of the main mechanisms of the cardiac effects 
of bupivacaine. This is mainly on the basis of cardiac sodium channels but block of 
transient and delayed potassium channels (29), and block of calcium channels are 
postulated also to have an effect (14). 
Severe ventricular arrhythmias after large doses of bupivacaine are the result of re-
entrant phenomena (24,30). A multitude of arrhythmias have been described due to 
bupivacaine including broad QRS complexes, ventricular ectopic beats, ventricular 
tachycardias, Torsade de Pointes, ventricular fibrillation, electromechanical dissociation 
and asystole. 
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Studies of the cardiac actions of Ropivacaine. 
Reiz et al studied the cardiotoxicity of ropivacaine (31 ). At doses adjusted to 
anaesthetic potency, lignocaine, bupivacaine or ropivacaine was infused into the left 
anterior descending artery of anaesthetised pigs. At high doses (16mg, 4mg or 5.33mg 
respectively), all 3 drugs significantly reduced by similar amounts the mean arterial 
pressure (approximately 10%) and left ventricular dP/dT (approximately 30%). The 
effects were seen 5 seconds after injection and were short lived, haemodynamics were 
back to control values within 60 seconds. Ropivacaine produced an increase of 30% in 
the great cardiac venous blood flow, suggesting that it is a coronary vasodilator. This 
effect was not seen with lignocaine or bupivacaine. The QRS interval was prolonged by 
75% due to the action of ropivacaine 5.33mg and by 155% after bupivacaine 4mg. 
Lignocaine did not affect the ventricular depolarisation time. None of the drugs had any 
significant effect on heart rate or cardiac output. They concluded on the basis of their 
results, that ropivacaine should be expected to have a 70% greater margin of safety than 
bupivacaine. They felt that the lower toxicity of ropivacaine is due not to the slightly 
shortened exposure to the myocardium, but to its lower lipid solubility. 
Arlock studied the effect of local anaesthetics on sodium channels in the guinea pig 
papillary muscle (13). He showed a more rapid dissipation after ropivacaine induced 
blockade, compared with bupivacaine blockade at equimolar concentrations. The 
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difference was however not sufficient to prevent accumulation of blockade although the 
block was lower with ropivacaine. 
Ropivacaine blocks open human delayed rectifier potassium channels in a concentration 
dependant manner. It seems however that ropivacaine has a lower affinity for these 
channels than bupivacaine (32). This may contribute to a lowered cardiac toxicity of 
ropivacaine as prolongation of the cardiac action potential is not as pronounced with 
ropivacaine compared to bupivacaine on the basis of potassium channel blockade. 
Moller and Covino compared the electrophysiologic properties of bupivacaine, 
lignocaine and ropivacaine (33). They used an isolated rabbit Purkinje fibre-ventricular 
muscle preparation. Only bupivacaine significantly decreased Purkinje fibre maximum 
diastolic potential. Action potential amplitude and maximal rate of depolarisation 
(Vmax), were significantly decreased by all agents in the order bupivacaine ~ 
ropivacaine ~ lignocaine. All three agents produced Purkinje fibre inexitability and 
Purkinje fibre-ventricular muscle conduction block. However, the duration of Purkinje 
fibre inexcitability after exposure to lignocaine and ropivacaine was significantly 
shorter than in the bupivacaine exposed group. Duration of the Purkinje fibre-
ventriclular muscle conduction block was shorter for ropivacaine than bupivacaine. 
They concluded that ropivacaine is less potent than bupivacaine but more potent than 
lignocaine in terms of its depressant effect on cardiac excitation and conduction. 
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The Pharmacology of Bupivacaine and Ropivacaine. 
The pharmacological effects of the two drugs are similar. Equal volumes and 
concentrations of ropivacaine and bupivacaine provide similar onset, quality and 
duration of sensory block when used for infiltration anaesthesia or peripheral nerve, 
brachia! plexus or extradural block (34). 
However there are significant pharmacokinetic differences between the two drugs. Both 
bupivacaine and ropivacaine are amide local anaesthetics and are derived from the 
parent compound mepivacaine. Both consist of a lipophilic aromatic group linked to a 
hydrophilic tertiary amine by an intermediate amide chain. 
CH, 
CF1 3 
11 , / 
Mepivacaine Bupivacaine 
CH, 
0 
CH, 
Ropivacaine 
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As can be seen from the above diagrams, the structures are similar, ropivacaine having 
a propyl group on the piperidine nitrogen atom compared to the butyl group of 
bupivacaine. The centre of asymmetry for ropivacaine is shown. 
Differences in the 3 dimensional structure confer differences in the activity of 
enantiomers in the complex biological environment of the receptor (35). This property 
of the pipecoloxy lidides was known in the late 1960' s because the different 
enantiomers had different durations of action at the target receptor in neural tissue (36). 
These differences in biological activity are not surprising because individual 
enantiomers bind to receptors or enzymes, which are chiral amino acids with 
stereoselective properties. 
Bupivacaine is supplied as the racemic mixture of its S and R forms, although recently 
isomeric S-bupivacaine has become available and studies into its use are being 
undertaken. 
Ropivacaine is supplied as the S enantiomer, having an enantiomeric purity of 99.5%. It 
is prepared by the alkylation of the S-enantiomer of dibenzoyl-L-tartaric acid. 
Bupivacaine is 95% protein bound, mainly to alpha- I-acid glycoprotein but also to 
albumin (3 8). The protein binding of ropivacaine is similar at 90%. Although highly 
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protein bound, the ratio of free to bound drug increases rapidly as the concentration 
increases (39). This has importance in situations where a large dose is given rapidly. 
The pKa of both bupivacaine and ropivacaine is 8.1 at 25°, which means that 
significant changes in the ratio of ionised to unionised drug may occur with changes in 
body pH (40). 
The partition coefficient of bupivacaine (octanol/phosphate buffer pH 7.4) is 309. It is 
therefore highly lipid soluble and this increases the potency, increases the speed of 
onset and prolongs the duration of its effect. The lipid solubility of ropivacaine is 
significantly less than that of bupivacaine and this is the main cause of the differing 
degree of motor block seen with these two agents ( 41 ). 
Ao and C fibres transmit pain sensation whereas large Aa fibres transmit motor 
impulses. In vitro most local anaesthetic drugs block C fibres at approximately the 
same rate. The rate of A fibre block depends on the physicochemical properties of the 
individual drugs with high pKa and low lipid solubility favouring block of C fibres 
before A fibres. 
The high lipid solubility of bupivacaine confers benefit by reducing absorption from the 
intended site of action e.g. the extradural space. However, this property is not relevant 
if this site is bypassed when the drug is injected directly into the circulation, as when a 
large dose is injected intravenously. In this situation it is transported directly to the 
heart and brain, where it presents a high concentration of free drug available to cross 
21 
the lipoprotein membrane ( 42). In addition, after accidental intravenous injection the 
mass of plasma protein in the volume of blood exposed to the drug is quickly saturated, 
leaving a significant amount of unbound drug available for diffusion into the 
conducting tissue of the heart and into the brain. Diffusion will obviously be faster with 
bupivacaine, possibly resulting in worse toxicity than with the less lipid soluble 
rop1vacame. 
Molecular Weight pKa(25°C) Distribution Protein Binding 
Coefficient 
Bupivacaine 288 8.1 346 95% 
Ropivacaine 274 8.1 115 90% 
Table 1. (43) 
Volume of Clearance Hepatic Terminal Mean body 
distribution (1/min) extraction elimination residence time 
(litres) ratio half life (h) (h) 
Bupivacaine 73 0.58 0.38 2.7 2.1 
Ropivacaine 61 0.73 0.49 1.9 1.4 
Table 2. (42) 
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The clearance of the amide local anaesthetics is mainly by liver metabolism and renal 
excretion of the metabolic products. The major metabolic reactions are aromatic 
hydroxylation, N-dealkylation and amide hydrolysis. The pharmacokinetics of 
ropivacaine and bupivacaine after intravenous and extradural administration have been 
determined in the dog and the Rhesus monkey ( 44,45). The concentration of 
ropivacaine decreases more rapidly than bupivacaine during the elimination phase after 
intravenous infusion. Mean clearance for ropivacaine in the dog was 41.1 ± 8.2 
ml/min/kg and for bupivacaine it was 32.3 ± 4.8 ml/min/kg. This was similar after 
extradural dosage. 
The pharmacokinetics of ropivacaine in human volunteers after intravenous infusion 
have been determined (46). Clearance was found to be 0.82 ± 0.16 l/min. This is higher 
than the value for bupivacaine which is 0.58 l/min. 
The higher clearance of ropivacaine compared with bupivacaine may offer an 
advantage in terms of systemic toxicity. 
From the foregoing it can be seen that ropivacaine is likely to be less toxic than 
bupivacaine on the pharmacokinetic basis of lower fat solubility and increased 
clearance. In addition the fact that ropivacaine is a pure enantiomer has been shown to 
be important. 
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Chirality. 
The observation that differences in drug pharmacology may be due to chirality has 
gained importance in recent years ( 4 7). This is due in part to the fact that modem 
technology allows the separation of or the optically pure synthesis of many drugs that 
were previously administered as racemic mixtures. Several reviews have appeared in 
recent years concerning chirality and local anaesthetics ( 48,49,50,34,51 ). 
Definitions: 
Isomers: Two or more different substances that have the same molecular formula, may 
be structural or stereoisomers. 
Structural Isomers: These have the same chemical formula but the atoms are not 
arranged with the same configuration so they have distinct chemical and physical 
properties (e.g. isoflurane and enflurane). 
Stereoisomers: These have the same chemical structure as each other but a different 3-
dimensional spatial configuration. There are right and left forms which are non-
superimposable mirror images. 
Geometric isomers: Are a form of stereoisomers but not always true mirror images of 
each other. They occur when two different groups are attached to each other by rigid 
covalent bonds that cannot rotate ( e.g. cis trans isomerism). 
Chiral compounds: Chiral means having 'handedness ' . A chiral compound is a 
substance with a centre of molecular asymmetry, such as a carbon atom with four 
different atoms or groups linked to it. Due to this asymmetry it is possible to have 
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different 3 dimensional spatial configurations of the molecule, which are mirror images 
of each other. These are known as stereoisomers, optical isomers or enantiomers. 
Optical isomers have the property of rotating plane polarised light giving rise to the 
system of nomenclature based upon the relative direction of rotation ( clockwise: d/ 
dextro/ +, counterclockwise: 1/ laevo/-) 
Further nomenclature is confusing, as there are at least three different naming systems. 
In addition to the optical rotation the absolute configuration can be defined according to 
a set of rules (Cahn-Ingold-Prelog system). This is based on the groups of the molecule 
and each centre of chirality is given a name R, rectus or S, sinister. The relative 
configuration implies a comparison to D ( +) glutaraldehyde denoted as D or L and 
should not be confused with d or 1, which have a different meaning. 
Racemic mixture: A mixture of equal concentrations of each isomer. A solution of a 
racemic mixture does not rotate plane, polarised light. A single stereoisomer, free from 
its enantiomer is referred to as enantiopure. A racemic mixture consists of equal 
amounts of both enantiomers. Natural chiral drugs are usually enantiopure as they are 
synthesised enzymatically and enzymatic reactions usually produce one enantiomer 
only e.g. atropine or morphine. 
Most synthetic chiral drugs are racemes because chemical reactions have an equal 
probability of producing both enantiomers. 
Enantiomers often differ in their pharmacological actions. This is due to the body being 
a chiral environment. Enantioselective pharmacology occurs where a chiral drug 
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interacts with an endogenous chiral centre, e.g. a receptor binding protein, metabolising 
enzyme or biomembrane. 
The ultimate action of the raceme is a weighted mean of the actions of the components. 
Ropivacaine is a single enantiomer, the S-(-)-N-n-propyl homologue of the S-(-) 
enantiomer of the mepivacaine/bupivacaine series. Laevobupivacaine, S-(-) 
bupivacaine, is a newly released form of bupivacaine and has been investigated 
regarding its efficacy and toxicity . 
Bupivacaine enantiomers differ in their properties at the site of action (52) . The same 
enantiomers exert different effects on the heart. Some studies have shown that S(-) 
bupivacaine is less cardiotoxic than R(+) bupivacaine (37,53). It seems that the S(-) 
enantiomer binds less tightly than the R( +) enantiomer to serum proteins but this may 
have two different effects. An increased free fraction leads to an increased hepatic 
clearance of bupivacaine so increasing safety, but in the case of massive overdose the 
increased level of free bupivacaine may in fact contribute to worse toxicity. However, 
the balance seems to be in favour of the use of the S(-)enantiomer. 
In neural sodium channels, R-bupivacaine associates 3 times as firmly as S-bupivacaine 
and dissociates 4.4 times as slowly, with the net effect that R-bupivacaine has a cardiac 
sodium channel dwell time 3 times as long as that of S-bupivacaine (52). Gristwood et 
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al have shown that R-bupivacaine prolongs ventricular conduction 4.6 times as much as 
S-bupivacaine, which renders R-bupivacaine severalfold more proarrhythmic than S-
bupivacaine (54). These observations suggest that the potential cardiotoxicity of R-
bupivacaine is far greater than that of S-bupivacaine. 
Heavner in 1986 made an important discovery when he noted that as little as 300µg of 
bupivacaine injected into the cerebral ventricle has distant cardiac effects and it 
suddenly became evident that bupivacaine cardiotoxicity was a dual phenomenon of 
direct cardiac toxicity plus some kind of neurogenic action (55). Shortly after this 
Thomas et al (56) performed a study where they injected lignocaine or bupivacaine 
directly into the Cl region or the intermediolateral column or the nucleus tractus 
solitarius of the rat medulla. They showed that both drugs into the C 1 area decreased 
mean arterial blood pressure, and at the intermediolateral column resulted in significant 
bradycardia and hypotension. At the nucleus tractus solitarius both caused bradycardia 
and hypotension, which was accompanied by ventricular arrhythmias. All animals 
receiving lignocaine survived, but 50% of the animals developing arrhythmias in the 
bupivacaine group died. In addition, R-bupivacaine has a more potent depressant effect 
on brainstem cardiorespiratory neurones, than the S enantiomer. The toxic effect of 
bupivacaine on electrical conduction through the heart is therefore compounded by an 
effect on indirect control, mediated by excited proarrhythmic and apneustic medullary 
command centres. This effect is strongly stereoselective for the R enantiomer and was 
established by Denson et al (57). They inserted electrodes into the nucleus tractus 
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solitarius and measured the cell-firing rate, after infusion of either isomer of 
bupivacaine. This was much lower after R bupivacaine and the incidence of 
hypotension, bradycardia and death was much higher in this group. 
However, this effect of direct cardiotoxicity plus indirect neurogenic cardiotoxicity is 
only apparent when the drug's free plasma level increases rapidly, as in accidental 
intravenous injection. In clinical practice, slow incremental injection has rendered 
bupivacaine extremely safe although mishaps occasionally occur. 
The foregoing would seem to suggest that ropivacaine, being the S(-) enantiomer, 
should be a safer drug in terms of cardiovascular side effects. 
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Treatment of Local Anaesthetic Toxicity. 
Resuscitation should take place along well-established management protocols, as for 
any case of cardiovascular or respiratory arrest, with attention to airway, ventilation and 
maintenance of cardiac output. Hypoxia and acidosis should be prevented or treated, as 
there is evidence that these are deleterious. Kotelko et al induced cardiotoxicity in 
tracheostomised sheep but was able to show a low mortality due, they thought, to 
avoidance of hypoxia or hyperkalaemia (20). Mets et al suggest that death in the rats 
studied was most likely due to respiratory arrest and circulatory arrest was due to a 
combination of hypoxia, acidosis and local anaesthetic toxicity (21 ). De Jong showed 
that in well ventilated and oxygenated cats, correction of hypotension by the use of 
ephedrine and maintenance of ventilation were important in the treatment of 
cardiovascular toxicity induced by bupivacaine. Mallampati suggests that prevention of 
hypoxia is associated with a successful resuscitation after bupivacaine toxicity, 
reporting a case in which bupivacaine toxicity was treated with aggressive 
cardiorespiratory support (23). 
The use of drugs in the treatment of established local anaesthetic toxicity is 
controversial. 
Although lignocaine has been used to treat ventricular arrhythmias induced by 
bupivacaine, Mets (21) et al showed an additive toxic effect when either bupivacaine 
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0.5%, or lignocaine 2% or a mixture of 1 % lignocaine and 0.25% bupivacaine was 
infused into rats. De La Coussaye (58) questioned the wisdom of using a local 
anaesthetic to treat local anaesthetic toxicity as both have an effect on ventricular 
conduction causing re-entrant arrhythmias 
The use of adrenaline is also controversial. Very high doses of adrenaline were used to 
successfully resuscitate rats after bupivacaine overdosage (59). Adrenaline was also 
successfully used to resuscitate dogs overdosed with bupivacaine ( 60), but was of no 
value in attempts to resuscitate sheep in another study (61). Feldman noted that 
multiple doses of adrenaline were not effective in resuscitating dogs with bupivacaine 
induced cardiotoxicity and that it caused ventricular tachycardia and hypertension in 
one dog with ropivacaine induced toxicity (62). He suggested that phenylephrine may 
be a better choice of vasopressor. In the absence of clear guidelines, it was decided that 
in this study, resuscitation would take place along standard protocols using adrenaline 
as the first line treatment for ventricular arrhythmias and severe hypotension. 
Atropine, beta receptor antagonists, benzodiazepines and noradrenaline have all been 
studied as treatment for local anaesthetic induced toxicity but no firm recommendation 
can be made concerning their use. Likewise calcium channel blockers, clonidine, 
dobutamine, hexamethonium and pacemakers have been suggested (63). 
30 
Solomon (64) et al showed that magnesium sulphate given to establish therapeutic 
concentrations prior to bupivacaine infusion, raised the threshold for cardiotoxicity. 
Magnesium as the drug of choice for treatment of bupivacaine induced cardiotoxicity 
has been studied by Reed (63). He studied the effect of a bolus of magnesium on the 
electrophysiological abnormalities induced by an infusion of bupivacaine in rats. He 
was able to show that magnesium produces a more rapid resolution of bupivacaine 
induced electrophysiological changes than placebo. It was decided on the basis of this 
work, to use magnesium as the anti arrhythmic agent in this study, should adrenaline 
and DC cardioversion fail to restore sinus rhythm after local anaesthetic induced 
arrhythmias. 
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Studies Comparing the Toxicity of Ropivacaine and Bupivacaine. 
Rutten et al studied the effect on the cardiovascular and central nervous systems of 
intravenous administration of lignocaine, bupivacaine and ropivacaine ( 65). They 
administered bolus doses of the local anaesthetics in sequentially increasing doses to 18 
conscious, instrumented sheep. The doses were administered into a central vein over 5 
seconds and the sheep were observed for CNS and CVS effects. After doses of local 
anaesthetic agents that did not cause convulsions, there were minimal cardiovascular 
effects. After doses that produced convulsions, there were marked increase in heart rate, 
mean arterial pressure, cardiac output, pulmonary artery pressure, systemic vascular 
resistance, left ventricular end diastolic pressure and dP/dt (left ventricular 
contractility). 2 sheep died after bupivacaine 80mg, one died after 90mg ropivacaine 
and one died after ropivacaine 120mg. 
The same team then examined the mechanisms of death after fatal doses of the same 
agents (22). 4 awake, instrumented sheep were given lignocaine, 4 bupivacaine and 4 
ropivacaine by infusion over 3 minutes. Fatal doses were established by treating the 
sheep with successive daily dose increments of each drug. The mean fatal dose of 
lignocaine was 30.7mg/kg, that ofbupivacaine was 3.7mg/kg and that of ropivacaine 
was 7.3mg/kg. 3 of the bupivacaine group died after sudden onset of ventricular 
tachycardia/fibrillation without hypoxia or acidosis. The fourth died of respiratory 
depression with bradycardia and hypotension as did the lignocaine treated animals. The 
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ropivacaine treated animals died of a combination of these two mechanisms. When the 
fatal doses of bupivacaine was compared to those of ropivacaine divided by 1.5 to 
compensate for the lower anaesthetic potency of ropivacaine, there was no significant 
difference between the 2 groups. This is important in terms of potential recovery as if 
severe cardiac toxicity occurs, it would be useful to establish that resuscitation is likely 
to be more successful after a toxic dose of ropivacaine. The authors suggest that 
ropivacaine has electrophysiological effects intermediate to those of bupivacaine and 
lignocaine. The proportion of the administered dose found in the heart and brain were 
similar for all three agent implying that the observed differences in toxicity were due to 
qualitative differences with respect to the effects of the agents on cardiac 
electrophysiology. 
The systemic toxicity of lignocaine, bupivacaine and ropivacaine has been studied in 
dogs (66). Feldman designed an experiment to mimic the accidental intravenous 
administration of a local anaesthetic and assessed the systemic toxicity, 
arrhythmogenicity and mode of death of convulsant and supraconvulsant doses of 
lignocaine, bupivacaine and ropivacaine. The experiment was performed on conscious 
dogs. Each dog was given a local anaesthetic on up to 3 consecutive days in increasing 
dosage. On the first day the drugs were infused until convulsions occurred. The average 
doses of each drug to cause convulsions, was 20.8mg/kg for lignocaine, 4.3 lmg/kg for 
bupivacaine and 4.88mg/kg for ropivacaine. The next day twice that dose was given 
and the response assessed. 2 dogs given lignocaine died due to progressive 
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hypotension, respiratory arrest and cardiovascular collapse. No ventricular arrhythmias 
were seen in this group. Ventricular arrhythmias were seen in 5 out of 6 dogs treated 
with bupivacaine and 4 died because of hypotension, respiratory arrest and 
cardiovascular collapse. A fifth dog died in ventricular fibrillation. In the ropivacaine 
group one animal died due to hypotension, respiratory arrest and cardiovascular 
collapse. Another dog had transient premature ventricular contractions. On the third day 
the surviving animals were given three times the convulsant dose i.e. for bupivacaine 
and ropivacaine the dose was 12.93mg/kg and 14.64mg/kg respectively. The remaining 
3 dogs in the lignocaine group, the last dog in the bupivacaine group and four dogs in 
the ropivacaine group died. Deaths were due to hypotension, respiratory arrest and 
cardiovascular collapse. 
The conclusions made were that the convulsive doses for ropivacaine and bupivacaine 
are similar but that ropivacaine has a greater margin of safety and is less 
arrhythmogenic than bupivacaine. The mean doses given in the study I am presenting 
were 21.2mg/kg for bupivacaine, and 20. lmg/kg for ropivacaine. These are 
significantly higher than those given by Feldman. 
Feldman's group then looked at the treatment of acute systemic toxicity of the local 
anaesthetics (62). They again established the convulsant dose of bupivacaine 
(4.3mg/kg) and ropivacaine (4.9mg/kg) and followed this with twice this dose 2 days 
later. Seizures at this time were treated with thiamylal and the dogs were intubated and 
34 
ventilated with oxygen enriched air. Two dogs in the bupivacaine group developed 
hypotension, respiratory arrest, ventricular tachycardia and fibrillation, which was 
resistant to closed chest massage, treatment with adrenaline, bretylium and atropine and 
DC cardioversion. The 4 remaining dogs survived after being successfully resuscitated 
by treatment of seizures and ventilation alone. All 6 dogs given ropivacaine survived 
without requiring any major intervention apart from intubation and treatment of 
seizures. They concluded that the rapid aggressive treatment of CNS and CVS toxicity 
can reduce the mortality associated with rapid intravenous administration of a local 
anaesthetic agent. The difference in mortality rates was not statistically significant 
although all dogs in the ropivacaine group survived compared to 66% of the dogs 
treated with bupivacaine. In this study, severe cardiotoxicity was not seen in the 
majority of dogs studied, as the dose of local anaesthetic was not enough to cause 
arrhythmias and hypotension. In contrast, the study I am presenting deliberateiy ensures 
severe cardiac depression to the point of cardiac arrest before resuscitation is attempted. 
A study by Reiz (31) in pigs showed a greater margin of safety of ropivacaine 
compared to bupivacaine injected directly into the left anterior descending artery. 
Anaesthetised pigs were studied by administering lignocaine, bupivacaine and 
ropivacaine in equi-analgesic doses. The favourable cardiotoxic profile of ropivacaine 
was confirmed and the toxicity ratio based on the electrophysiological effect of 
35 
prolongation of the QRS complex was determined as 1: 6.7: 15 for lignocaine: 
ropivacaine: bupivacaine. 
Bupivacaine has also been shown to be more cardiotoxic than an equivalent dose of 
ropivacaine, in the isolated perfused rabbit heart. It caused more severe arrhythmias 
than ropivacaine and the development of ECG changes and myocardial depression was 
more rapid with bupivacaine (67). 
Several other studies have reported the safety of ropivacaine compared to bupivacaine 
both in animal studies and in humans. Santos et al compared the effect of infusing 
ropivacaine and bupivacaine into pregnant and non-pregnant sheep and concluded that 
toxicity was not worsened by gestation ( 68). The dose of ropivacaine required to 
produce circulatory collapse was 12.9mg/kg compared to 8.5mg/kg for bupivacaine. 
Scott et al compared the acute toxicity of bupivacaine and ropivacaine (69) . They 
studied 12 healthy male volunteers who received both drugs as an infusion at 1 Omg/min 
7 days apart. The occurrence of CNS symptoms was the cue to terminating the infusion 
but a dose of 150mg of local anaesthetic was the maximum allowed by the protocol. 
The mean doses infused were 124mg of ropivacaine and 99mg ofbupivacaine. Only 1 
out of 12 subjects tolerated 150mg of bupivacaine compared to 7 out of 12 who 
tolerated 150mg of ropivacaine. Both drugs increased heart rate and arterial pressure 
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with a reduced stroke volume and ejection fraction, but cardiac output was maintained. 
Prolongation of the PR interval, QRS duration and QT interval was seen with 
bupivacaine but not ropivacaine. 
Knudsen et al performed a similar experiment. They infused bupivacaine and 
ropivacaine into human volunteers until CNS toxicity occurred (70) . The maximum 
tolerated dose was higher after ropivacaine in 9 subjects (mean 115mg) and higher after 
bupivacaine in 3 subjects (mean 103mg). The maximum tolerated unbound arterial 
plasma concentration was twice as high after ropivacaine but the time to disappearance 
of all symptoms was shorter after ropivacaine. At doses producing CNS symptoms 
cardiovascular changes were less significant with ropivacaine: the QRS width was 
increased more by bupivacaine and there was a greater effect on contractility from 
bupivacaine as assessed by echocardiography. 
In summary, most studies comparing the toxicity of ropivacaine with that of 
bupivacaine have shown ropivacaine to be less toxic in terms of dosage and direct 
toxicity. There seems to be no doubt that ropivacaine is less likely than bupivacaine to 
cause problems with cardiovascular toxicity in clinical use. However, if severe 
cardiovascular depression does occur, there is no published evidence that resuscitation 
will be more successful after ropivacaine. 
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Method. 
The aim of the experiment was to establish whether, after deliberately induced cardiac 
arrest by overdosage of a local anaesthetic agent, resuscitation was more successful 
after administration of ropivacaine compared to bupivacaine. 
Male pigs were chosen as the model for the experiment. Ethical approval was granted 
by the Animal Research Review Committee, of the Faculty Medicine, of the University 
of Cape Town. 
The study was performed in two parts. Experiment 1 was a pilot study, with the 
expectation that the survival in the pigs treated with ropivacaine would be far greater 
than in the bupivacaine treated group. 
Power analysis indicated that a sample size of 12 pigs would be required to show a 
statistically significant difference if there were 4 deaths in the bupivacaine group and 
none in the ropivacaine group. 
Experiment 2 was a modification of experiment 1, the difference being in the rate of 
infusion of the test drug, as it became apparent that the rate of infusion could have 
influenced the outcome of the experiment. 
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The investigators were blinded as to the identity of the infused drug. 
In each experiment, the 12 pigs were randomised to receive either ropivacaine or 
bupivacaine, 6 in each group. 
The pigs were anaesthetised by administration of ketamine 1 Omg/kg intramuscularly 
followed by atropine 0.5mg IM. Intravenous access was established and thiopentone 
3mg/kg plus fentanyl lOµg/kg given intravenously. The pigs were intubated and a bolus 
of pancuronium O.lmg/kg IV was given. Subsequent maintenance consisted of 
intermittent positive pressure ventilation with nitrous oxide, oxygen and halothane. The 
halothane was discontinued 20 minutes prior to administration of the local anaesthetic 
agent. All pigs had previously been tested for susceptibility to malignant hyperthermia. 
Vascular access consisted of an arterial line in each carotid artery, one for monitoring of 
blood pressure and the other for blood sampling. A central venous line was inserted into 
the internal jugular vein for infusion of drugs and central venous pressure monitoring. 
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Monitoring consisted of an ECG, arterial blood gases and rectal temperature probe in 
addition to invasive blood pressure monitoring. The temperature was maintained 
between 36° and 38° by use of a warming fan. 
Sodium chloride 0.9% with 5% dextrose was given intravenously at 2-5ml/kg/hr to 
maintain blood pressure as required. 
Once vascular access was established, a bolus of fentanyl lOµg/kg was given IV and a 
left lateral thoracotomy was performed in order to expose the heart for internal cardiac 
massage. Once this was complete the halothane was discontinued and blood gases 
checked to confirm oxygenation and normocapnia. The ventilation was adjusted as 
required at this point. 
In experiment 1, the local anaesthetic given consisted of either bupivacaine 0.5%, 
5mg/kg bolus, followed by an infusion of lmg/kg/min, or ropivacaine 1 %, lOmg/kg 
bolus, followed by an infusion of 2mg/kg/min. These doses were calculated on the basis 
of work done by Feldman (62) and Nancarrow (22) and were felt to be sufficient to 
cause cardiac arrest shortly after the bolus dose was injected, with the subsequent 
infusion ensuring that the arrest occurred. The infusion was continued until cardiac 
arrest and was then stopped. At cardiac arrest, blood was taken for local anaesthetic 
levels, and resuscitation started. Cardiac arrest was defined as a systolic blood pressure 
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of less than 30mmHg, or pulseless ventricular tachycardia, or ventricular fibrillation, or 
asystole. 
Resuscitation was performed according to the guidelines of the Resuscitation Council 
(UK) of 1997 (72). 
Survival was defined as the maintenance of a spontaneous regular cardiac rhythm with 
a mean blood pressure of at least 50mmHg for the last 30 seconds of the 15 minute 
period. 
Any pig deemed a survivor at the termination of the experiment was given a bolus of 
potassium chloride as euthanasia. 
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Resuscitation. 
Ventricular fibrillation or pulseless ventricular tachycardia. 
100% oxygen was given. 
Immediate defibrillation with internal paddles was performed with 4 joules, repeated 
with 4 joules and again with 8 joules if the previous shock was unsuccessful at 
defibrillating. 
Adrenaline 1mg IV was given and internal cardiac massage commenced at 80-100 
compressions per minute. 
DC cardioversion was repeated with 3 shocks at 8 joules after every minute of 
resuscitation or 60s after any intervention. Internal cardiac massage was continued as 
long as there was insufficient cardiac output. 
Adrenaline 1 mg IV was given every 3 minutes. 
Blood gases were checked at 8 minutes and acidosis corrected with sodium bicarbonate 
if the pH was less than 7.20 or the base excess greater than -10. 
Magnesium sulphate 60mg/kg IV was given at 12 minutes if the rhythm was ventricular 
tachycardia with no cardiac output, or ventricular fibrillation. 
The experiment was terminated at 15 minutes. 
Blood was taken at 15 minutes for measurement of the plasma concentration of the 
local anaesthetic. In survivors, blood was taken for local anaesthetic plasma 
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concentrations at resumption of stable CVS parameters. The local anaesthetic levels 
were measured using Gas Chromatography with a Nitrogen Phosphorous Detector. 
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NonVFNT. 
100% oxygen was commenced. 
Internal cardiac massage at 80-100 compressions per minute was performed. 
Adrenaline 1 mg was given IV every 3 minutes. 
Blood gases were checked at 8 minutes and corrected as required ( as in the VF 
protocol). 
The experiment was terminated at 15 minutes and blood taken for plasma levels of local 
anaesthetic. 
In survivors the local anaesthetic levels were measured at the resumption of stable 
cardiovascular parameters. 
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Results Experiment 1. 
The mortality in the ropivacaine treated pigs was 16% versus 50% in the bupivacaine 
group. 
The resuscitation of each pig followed the recommendations as above but the course of 
events during the arrest situation varied during each experiment. 
Pig 1. A wide complex bradycardia developed and after 450mg of drug the systolic 
blood pressure was <30mmHg. Adrenaline 1mg was given and after 30 seconds of 
internal cardiac massage a good cardiac output had resumed. No further resuscitation 
was required. Survivor. Drug: ropivacaine. 
Pig 2. A wide complex bradycardia occurred followed by ventricular fibrillation after 
3 80mg of drug. The protocol was followed with 3 DC cardioversion attempts and a 
total of 5mg of adrenaline. There was no need to correct the acid base status. At 12 
minutes magnesium sulphate was given. 60 seconds later resumption of sinus rhythm 
occurred with a rate of 42 beats per minute and blood pressure of 118/68. 
Survivor. Drug: ropivacaine. 
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Pig 3. A bradycardia with normal complexes developed which evolved into asystole 
after 730mg of drug. Adrenaline 1mg was given with simultaneous internal cardiac 
massage. Within 30 seconds a regular rhythm was established followed by the recovery 
of the blood pressure. No further resuscitation was required. During the completion of 
the 15 minute study period, multiple ectopic beats developed which although not 
causing haemodynamic instability were treated twice with a bolus of magnesium 
sulphate. Survivor. Drug: ropivacaine. 
Pig 4. A wide complex bradycardia progressed to asystole after 430mg of drug. Cardiac 
massage was commenced and adrenaline 1mg given. There was a good initial recovery, 
which developed after 3 minutes into ventricular fibrillation. DC cardioversion was 
unsuccessful and further adrenaline was given to a total of 4 mg. Cardiac massage and 
further attempts at cardioversion were unsuccessful. The acid base status remained 
normal. Magnesium sulphate was given at 12 minutes. The cardiac rhythm degenerated 
to fine ventricular fibrillation and then asystole and was unresponsive to further 
resuscitation attempts. Non-survivor. Drug: ropivacaine. 
Pig 5. A wide complex bradycardia developed with hypotension and after 490mg of 
drug, when the systolic blood pressure was 30mmHg, adrenaline was given and cardiac 
massage commenced. There was a good response initially with regular wide complexes 
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at a rate of 97 and a blood pressure of 97178. No correction of blood gases was required 
and at 12 minutes there was sinus rhythm with a BP of 120/70. In spite of the 
satisfactory parameters magnesium was given and caused hypotension with wide 
complexes requiring 2 doses of adrenaline and DC cardioversion. There was a good 
response and this animal was alive at and beyond 15 minutes. Survivor. Drug: 
bupivacaine. 
Pig 6. There was initial hypotension with a wide complex bradycardia and a systolic BP 
<30mmHg after 540mg of drug. Adrenaline and cardiac massage were commenced and 
after 60 seconds there was resumption of a regular rhythm. At 6 minutes atropine 0.5mg 
was given for bradycardia followed 2 minutes later by adrenaline 1 mg for hypotension. 
This was followed by ventricular fibrillation so DC cardioversion at 41, 41 then SJ was 
performed. The rhythm remained VF and magnesium was given. A further 3 DC shocks 
were given followed by adrenaline 1mg and atropine 0.5mg given to treat a sinus 
bradycardia. This animal maintained an adequate spontaneous cardiac output at 15 
minutes. Survivor. Drug: bupivacaine. 
Pig 7. A wide complex bradycardia developed associated with hypotension until after 
700mg of drug the systolic blood pressure was <30mm Hg. After the initial adrenaline 
there was a good response but the pulse slowed and atropine 0.5mg was given. The 
blood pressure fell so another dose of adrenaline was given which was followed by 
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ventricular fibrillation. Further resuscitation consisted of DC shocks, adrenaline and 
magnesium. The acid base status remained satisfactory. This animal remained in VF 
until termination of the experiment. Non-survivor. Drug: bupivacaine. 
Pig 8. A sinus bradycardia developed with associated hypotension until 450mg of drug 
had been given when the BP fell to 30mm Hg. Cardiac massage was commenced 
followed by 3 doses of adrenaline and DC cardioversion at 9 minutes for VF. This was 
unsuccessful so another dose of adrenaline, and DC shock were given. At 12 minutes 
magnesium was given and this was followed by the resumption of sinus rhythm. There 
was no cardiac output associated with this rhythm so adrenaline was again given 
followed by brief cardiac massage. At 15 minutes the blood pressure was 126/86 and 
pulse in sinus rhythm at a rate of 59. (This animal was observed for a further 15 
minutes after the experiment was terminated, remaining stable throughout). Survivor. 
Drug: ropivacaine. 
Pig 9. Asystole occurred after 350mg of drug. Cardiac massage was commenced and 
adrenaline 1mg given. There was an immediate resumption of cardiac output and no 
further treatment was required. Survivor. Drug: ropivacaine. 
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Pig 10. Arrest in asystole occurred after 330mg of drug. Cardiac massage and 
adrenaline resulted in an immediate resumption of good cardiac output and no further 
treatment was required. Survivor. Drug: bupivacaine. 
Pig 11. Asystole occurred after 63 5mg of drug. After several doses of adrenaline, 
ventricular fibrillation occurred and this remained refractory to further treatment by DC 
shock and magnesium. The rhythm at 15 minutes was asystole. 
Non-survivor. Drug: bupivacaine. 
Pig 12. Bradycardia occurred evolving to asystole after 335mg of drug. Adrenaline 
initially restored the rhythm and blood pressure briefly, but this was followed by VF. 
This was unresponsive to further treatment with adrenaline, magnesium and DC shock 
and the rhythm was asystole at 15 minutes. Non-survivor. Drug: bupivacaine. 
The results are presented in Table 3 overleaf. 
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Pig number Weight(kg) Test Drug Dose(mg) Vol(ml) Dose(mg/kg) Outcome 
1 24.5 rop1vacame 450 45 18.4 survived 
2 22.0 rop1vacame 380 38 17.3 survived 
3 23.0 rop1vacame 730 73 31.7 survived 
4 23.0 rop1vacame 430 43 18.7 died 
5 23.0 bupivacaine 490 98 21.3 survived 
6 23.0 bupivacaine 540 108 23.5 survived 
7 25.0 bupivacaine 700 140 28.0 died 
8 22.0 rop1vacame 450 45 20.5 survived 
9 25 .0 rop1vacame 350 35 14.0 survived 
10 23.0 bupivacaine 330 66 14.3 survived 
11 25.0 bupivacaine 635 127 25.4 died 
12 23 .0 bupivacaine 335 67 14.6 died 
Table 3 
50 
Pig No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Local anaesthetic levels were measured at arrest and at 15 minutes or at recovery of 
stable cardiovascular parameters. 
Drug L.A. at arrest (µg /ml) L.A. at recovery/death (µg/ml) Outcome 
rop1vacame 87.7 14.9 survived 
rop1vacame 178.7 13 .6 survived 
rop1vacame 80.6 12.4 survived 
rop1vacame 102.1 35.8 died 
bupivacaine 128.4 21.2 survived 
bupivacaine 29.5 19.1 survived 
bupivacaine 53.0 18.2 died 
rop1vacame 54.6 16.4 survived 
rop1vacame 47.1 7.6 survived 
bupivacaine 32.7 17.6 survived 
bupivacaine 78.0 28.0 died 
bupivacaine 33.4 21.3 died 
Table 4. 
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The times to arrest and recovery are shown in table 5. 
Pig Number 1 2 3 4 5 6 7 8 9 10 11 12 
T to arrest(min) 4.7 4.1 11.4 5.0 16.8 18.9 23.5 4.7 2.7 9.8 20.9 10.0 
T to recov.(min) 1 13 1 15 1 14 15 15 1 1 15 15 
Drug 
Ropivacaine 
Bupivacaine 
Table 5. 
A summary of the results is presented in table 6. 
Mean weight Mean dose Mean dose/kg Mean time to Mean time to Mean blood level Mean blood level 
(kg) (mg) (mg) arrest (min) recovery (min) at arrest (µg/ml) at end (µg/ml) 
23.25 465 20.1 5.4 7.7 91.8 
± 3.0 ± 7.3 ±47.3 
23 .67 505 21.2 16.6 10.2 59.2 
± 5.7 ± 7.1 ± 38.5 
Table 6. 
There was no statistically significant difference between the 2 groups regarding the 
weights of the pigs, mean dose of local anaesthetic or mean dose per kilogram. The 
time to cardiac arrest was longer with bupivacaine and this was highly statistically 
significant (p = 0.002). However the time to recovery/death was not significantly 
different. There was no statistically significant difference in the blood levels of local 
16.8 
± 9.8 
20.9 
± 3.8 
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anaesthetic at arrest or at recovery. The difference in mortality (16% versus 50%) did 
not reach statistical significance. 
Arterial blood gases were also analysed for statistical significance. There was no 
difference in any of the parameters except the mean p02 was lower in the ropivacaine 
group, and this was statistically significant. However, the p02 was above normal at all 
times and not felt to be clinically important. The blood gas results and mean results are 
presented in table 7 and 8 respectively. 
53 
pH pC02 p02 Std Bicarb Base Excess 
Pig 1 pre infusion 7.54 3.52 24.92 25.9 +0.2 
Pig 1 post arrest 7.40 5.48 20.71 25.0 +0.7 
Pig 2 pre infusion 7.48 4.80 13.36 27.4 +2.9 
Pig 2 post arrest 7.55 3.17 50.11 25.1 -1.1 
Pig 3 pre infusion 7.47 4.73 16.89 27.1 +2.5 
Pig 3 post arrest 7.43 5.35 16.72 26.2 +1.9 
Pig 4 pre infusion 7.49 4.44 14.52 25.2 +2.8 
Pig 4 post arrest 7.62 1.93 45.90 21.8 -6.1 
Pig 5 pre infusion 7.57 4.03 29.90 31.0 +5 .8 
Pig 5 post arrest 7.74 2.11 65.30 29.6 +1.8 
Pig 6 pre infusion 7.51 4.60 38.40 27.6 +4.5 
Pig 6 post arrest 7.65 2.29 69.60 25.6 -1.5 
Pig 7 pre infusion 7.52 4.12 34.78 27.8 +2.8 
Pig 7 post arrest 7.54 2.95 67.31 23.3 -3.4 
Pig 8 pre infusion 7.45 4.96 29.01 26.6 +2.1 
Pig 8 post arrest 7.51 3.53 41.94 24.7 -1.2 
Pig 9 pre infusion 7.42 6.16 24.40 28.5 +5 .0 
Pig 9 post arrest 7.32 7.04 42.93 24.5 + 1.1 
Pig 10 pre infusion 7.41 5.73 32.58 26.5 +2.6 
Pig 10 post arrest 7.25 7.74 32.80 21.8 -1.6 
Pig 11 pre infusion 7.45 4.09 35.83 23.5 -2.1 
Pig 11 post arrest 7.54 4.06 25.04 28.0 +2.9 
Pig 12 pre infusion 7.49 4.89 17.95 29.0 +4.7 
Pig 12 post arrest 7.64 2.59 54.12 26.9 +0.3 
Table 7. 
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Mean blood gas results. 
pH pC02 p02 Std Bicarb Base excess 
Ropivacaine pre infusion 7.48 4.76 20.52 26.8 +2.6 
Bupivacaine pre infusion 7.49 4.57 31.56 27.6 +3.0 
Ropivacaine post arrest 7.47 4.41 36.38 24.6 -0.8 
Bupivacaine post arrest 7.57 3.62 52.36 25.9 -0.3 
Table 8. 
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Discussion Experiment 1. 
There was a statistically significant difference in the time of infusion to cause cardiac 
arrest (16.6 minutes for bupivacaine versus 5.4 minutes for ropivacaine) . This was felt 
to be contributory to the improved survival in the ropivacaine group, as it would have 
taken longer for cardiac levels of bupivacaine to reach toxic levels, during which time 
peripheral compartment would have become saturated with the drug. Despite the mean 
dose of drug being similar, the plasma level ofbupivacaine was much lower than that of 
ropivacaine at arrest (59.2µg/ml compared to 91.8µg/ml). This was probably due firstly 
to the larger volume of distribution of bupivacaine (731 versus 611), and secondly to the 
longer infusion time, allowing for a greater degree of redistribution to occur. This 
implies less facility for redistribution from the myocardium for bupivacaine, whereas 
the recovery from ropivacaine induced cardiac arrest could have been mainly due to 
redistribution 
Accordingly, Experiment 2 was a modification of Experiment 1. 
The bolus of drug given was unchanged, 5mg/kg for bupivacaine, and 1 Omg/kg for 
ropivacaine, these being the commercially available concentrations. 
56 
The infusion was altered. Bupivacaine was given as in Experiment 1, at a concentration 
of 0.5%. The ropivacaine was diluted with saline to give a concentration of 0.5%. The 
infusion rate of both drugs was lOml/minute ofthis 0.5% solution, therefore 50mg of 
each drug was given per minute. 
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Results Experiment 2. 
The mortality in the bupivacaine group was 50%, unchanged from Experiment 1. 
The mortality in the ropivacaine group was also 50%, up from 16% in Experiment 1. 
The sequence of events during the process of cardiac arrest and resuscitation during 
Experiment 2 was similar to the events of Experiment 1. The animals developed a wide 
complex bradycardia with hypotension to a systolic blood pressure of less than 
30mmHg. No animal developed ventricular tachycardia or fibrillation prior to the 
administration of adrenaline, although ventricular fibrillation was seen sometimes after 
adrenaline was given. The sequence of events for each animal will not be described 
further. 
Table 9 overleaf shows the results of Experiment 2. 
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Pig Number Weight(kg) Test Drug Dose(mg) Vol(ml) Dose (mg/kg) Outcome 
13 25 rop1vacame 510 77 20.4 survived 
14 23 rop1vacame 400 57 17.4 died 
15 25 bupivacaine 335 67 13.4 survived 
16 23 bupivacaine 390 78 17.0 died 
17 26 bupivacaine 380 76 14.6 died 
18 21 rop1vacame . 375 54 17.8 survived 
19 22 bupivacaine 400 80 18.2 died 
20 21 rop1vacame 420 63 20.0 died 
21 27 rop1vacame 355 46 13.2 died 
22 24 bupivacaine 285 57 11.9 survived 
23 23 bupivacaine 325 65 14.1 survived 
24 26 rop1vacame 450 64 17.3 survived 
Table 9. 
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The plasma levels of local anaesthetic at arrest and recovery/death are shown in table 
10. 
Pig number Drug L.A. at arrest (µg/ml) L.A. at recovery/death (µg/ml) Outcome 
13 rop1 vacame 94.o 14.1 survived 
14 rop1vacame 168.3 16.7 died 
15 bupivacaine 140.4 13.2 survived 
16 bupivacaine 113.3 22.8 died 
17 bupivacaine 68.3 25 .6 died 
18 rop1vacame 77.6 14.0 survived 
19 bupivacaine 105.3 33.0 died 
20 rop1vacame 131.8 33.9 died 
21 rop1vacame 19.9 15.5 died 
22 bupivacaine 173.4 16.3 survived 
23 bupivacaine 86.0 10.7 survived 
24 rop1vacame 33.5 5.6 survived 
Table 10. 
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Drug 
ropivacaine 
bupivacaine 
Times to arrest and recovery are shown in table 11. 
Pig number 13 14 15 16 17 18 19 20 21 22 23 24 
T to arrest( min) 5.2 3.4 4.2 5.5 2.5 3.3 5.8 4.2 1.9 3.3 4.2 3.8 
T to recovery(min) 13 15 1 15 15 2 15 15 15 11 1 1 
Table 11. 
A summary of the results of Experiment 2 is presented in table 12. 
Mean weight(kg) Mean dose Mean dose/kg Mean time to Mean time to Mean blood level Mean blood level at 
(mg) (mg) arrest (min) recovery (min) at arrest (µ g/ml) 
23.8 418 17.6 3.6 10.16 101.0 
± 1.1 ± 6.8 ± 51.6 
23.8 353 14.9 4.2 9.66 114.5 
± 1.3 ± 6.9 ± 37.9 
Table 12. 
There were no statistically significant differences in the weight of the pigs, mean doses, 
mean time to arrest or recovery, or mean plasma levels at arrest or recovery. The 
mortality was 50% for both groups. 
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end (µg/ml) 
16.7 
± 10.4 
20.3 
± 8.4 
The blood gas results are shown in table 13. 
pH pC02 p02 Std Bicarb Base Excess 
Pig 13 pre infusion 7.42 5.41 14.12 26.9 +2.7 
Pig 13 post arrest 7.30 6.75 13 .14 26.6 -1.4 
Pig 14 pre infusion 7.42 5.89 13.72 28.6 +4.6 
Pig 14 post arrest 7.76 1.78 53.90 28.0 +3 .9 
Pig 15 pre infusion 7.38 6.45 20.15 27.4 +3.2 
Pig 15 post arrest 7.66 2.26 78.26 26.7 +2.5 
Pig 16 pre infusion 7.63 2.47 20.30 26.3 +2.0 
Pig 16 post arrest 7.64 1.64 56.58 22.0 -3.0 
Pig 17 pre infusion 7.51 2.60 19.77 20.5 -4.9 
Pig 17 post arrest 7.52 2.93 39.16 22.5 -2.3 
Pig 18 pre infusion 7.59 2.90 15.53 25.8 +1.5 
Pig 18 post arrest 7.41 3.88 62.10 20.9 -4.4 
Pig 19 pre infusion 7.60 3.60 11.20 30.0 +6.2 
Pig 19 post arrest 7.59 2.39 59.20 23.0 -1.7 
Pig 20 pre infusion 7.65 2.29 13.88 29.2 +5.3 
Pig 20 post arrest 7.50 3.68 40.08 24.8 +0.4 
Pig 21 pre infusion 7.52 4.76 11.20 30.3 +6.6 
Pig 21 post arrest 7.44 4.48 7.62 23.8 -0.5 
Pig 22 pre infusion 7.53 4.13 15.85 28.2 +4.2 
Pig 22 post arrest 7.58 3.13 72.13 26.6 +2.4 
Pig 23 pre infusion 7.49 4.20 33 .86 25.8 +1.6 
Pig 23 post arrest 7.38 4.99 64.40 22.5 -2.4 
Pig 24 pre infusion 7.47 4.90 16.13 26.8 +3.7 
Pig 24 post arrest 7.29 6.61 17.33 23.5 -3.0 
Table 13 . 
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The mean arterial blood gas results are shown in table 14. 
pH pC02 p02 Std Bicarb Base Excess 
Ropivacaine pre infusion 7.51 4.36 14.09 27.9 
Bupivacaine pre infusion 7.46 3.91 20.18 26.4 
Ropivacaine post arrest 7.44 4.24 32.36 24.6 
Bupivacaine post arrest 7.56 2.89 61.62 23 .9 
Table 14. 
There was a statistically significant difference in the post arrest p02 but other 
parameters were similar. This difference was not felt to be clinically significant. 
+4.0 
+2.1 
-0.8 
-0.8 
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Discussion. 
For both pharmacokinetic and pharmacodynamic reasons, ropivacaine may be expected 
to have a more benign effect on the heart than bupivacaine, and resuscitation from local 
anaesthetic overdose could be expected to be more successful with ropivacaine. 
In terms of pharmacokinetics, firstly, the clearance ofropivacaine is greater than that of 
bupivacaine so the effect of ropivacaine on the myocardium could be expected to 
dissipate more rapidly than that of bupivacaine (46) . Secondly, as the fat solubility of 
bupivacaine is much greater than that of ropivacaine, it will more rapidly cross 
lipoprotein membranes to enter the myocardial cells to a greater extent than 
ropivacaine, thus gaining access to ion channels which can then be blocked, resulting in 
toxicity ( 42). 
In terms of pharmacodynamics, ropivacaine has a more favourable profile compared to 
bupivacaine. There is less block of sodium channels (13), less block of potassium 
channels (32), and less block of calcium channels with ropivacaine compared to 
bupivacaine (14 ). This suggests that the effect on V max of ropivacaine is less than 
ropivacaine and that this effect is less amplified by blockade of calcium and potassium 
channels. The R isomer of bupivacaine has a much higher affinity for neural sodium 
channels than the S isomer and prolongs ventricular conduction 4.6 times as much as S-
bupivacaine (54), thus the S isomer ropivacaine may be suspected of having similar 
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properties, thus being more benign. R-bupivacaine also has a greater effect on 
brainstem cardiorespiratory neurones than the S isomer (57), and R-ropivacaine has 
been shown to be more cardiotoxic than S-ropivacaine (71). Ropivacaine has also been 
shown to be a coronary vasodilator (31 ), increasing great cardiac venous blood flow, 
thus hastening its clearance from myocardial cells. 
In each of the two experiments performed, the doses of drug infused to cause 
cardiotoxicity were similar on a mg/kg basis. However, in Experiment 1, on a ml/kg 
basis the volume of bupivacaine infused was more than twice that of ropivacaine (a 
mean of lOlmls for bupivacaine versus 46.5ml for ropivacaine). This poses several 
questions regarding the experiment. It was initially thought that the bolus of each drug 
would be sufficient in terms of cardiotoxicity to necessitate only a short infusion prior 
to cardiac arrest. This calculation was based on the work of Feldman (62) and 
Nancarrow (22). Feldman studied the toxic doses of bupivacaine and ropivacaine and 
found that cardiovascular collapse occurred after an infusion of 8.62mg/kg of 
bupivacaine resulting in 4 deaths out of 6 dogs, and 22.8mg/kg of ropivacaine resulting 
similarly in 4 deaths out of six dogs . Nancarrow established the mean fatal dose of 
bupivacaine in sheep as 3.7mg/kg and ofropivacaine as 7.3mg/kg. 
The pigs in the first experiment of this study were given either 5mg/kg of bupivacaine 
or lOmg/kg ofropivacaine as a bolus followed by an infusion of lmg/kg/min or 
2mg/kg/min for bupivacaine and ropivacaine respectively. The time to arrest was 
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approximately three times longer in the bupivacaine group once the infusion had 
started. This implies that significant redistribution of drug had already occurred by the 
time cardiac arrest occurred, which implies less facility for redistribution once 
resuscitation had started, as peripheral compartments can be considered as virtually 
saturated. The blood level of bupivacaine fell from 59.2µg/ml to 0.35 of that level, 
20.9µg/ml. For ropivacaine, toxicity occurred sooner, and some of the success in 
resuscitation may be due to rapid redistribution from the heart whereas this mechanism 
may not have been available to the bupivacaine treated pigs. The ropivacaine plasma 
levels fell from 91.8 to 20.9µg/ml, 0.18 of the arrest values implying a very much 
greater clearance from the blood than bupivacaine. This difference was statistically 
significant (p = 0.019). In Experiment 2, this difference was eliminated, both falling to 
approximately one fifth of the arrest level. This enabled a more direct comparison of 
the two drugs. 
In Experiment 1 the cardiovascular parameters may have been influenced by the effect 
of the volume alone. Based on a blood volume of 70ml/kg, the mean volume of drug 
infused represents approximately 6% of blood volume for bupivacaine and only 3% for 
ropivacaine. A rapid infusion of such magnitude may have had deleterious effects on a 
heart being subjected to negative inotropism and arrhythmias, and may also have 
contributed to a worse outcome in the bupivacaine group. Experiment 2 corrected for 
this, and similar volumes of local anaesthetic were given to cause cardiac arrest. 
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An interesting observation was that in none of the 24 pigs studied, did an acidosis 
develop during the arrest period, as shown by the blood gas results at 8 minutes. The 
cardiac output was maintained by internal cardiac massage and was seen to be effective 
in maintaining a mean blood pressure of approximately 30 - 40mrnHg during the arrest 
period. As mentioned previously it has been noted that avoidance of hypoxia and 
acidosis is important for a successful resuscitation post bupivacaine cardiotoxicity 
(61 ,23). A contributing factor in the reported high mortality due to local anaesthetic 
toxicity, is that it is likely that in some cases, airway management problems with 
ineffective external chest compressions resulting in a low cardiac output may have led 
to a persistent metabolic acidosis due to hypoxia. In this study, the maintenance of an 
adequate cardiac output has avoided this problem. The extrapolation of animal model 
results to the situation in humans may not be valid but as a general principal of 
resuscitation, oxygen delivery must be maintained, and if cardiac output cannot be 
assured by external cardiac massage, consideration of internal cardiac massage is 
warranted. 
Another interesting finding was that in each experiment, the dose to cause 
cardiovascular collapse was similar for both drugs (the doses in Experiment 2 were 
lower due to a more rapid infusion of the test drug resulting in earlier toxicity). This is 
in contrast to most studies, which show cardiovascular collapse at a lower dose for 
bupivacaine. This may be due to the fact that the effect on the heart alone was studied 
here while providing ventilatory support throughout the drug infusion period during 
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which cardiac toxicity was developing. There has been no study comparing the cardiac 
toxicity of ropivacaine and bupivacaine in ventilated animals. Previous studies have 
looked at the effect of these agents in spontaneously breathing animals, which develop 
CNS symptoms followed by CVS symptoms. Ropivacaine tends to be used in similar 
or slightly higher concentrations than bupivacaine, implying that the dose required to 
achieve an effect is similar for both agents. Most studies show cardiac complications 
after a higher dose of ropivacaine compared to bupivacaine. 
The local anaesthetic levels of all 24 pigs were examined as a combined group. There 
was a highly statistically significant difference in the plasma level of local anaesthetic 
in survivors compared to non-survivors (14.3 ± 4.2µg/ml compared to 26.8 ± 7.0µg/ml, 
p = 0.001). The local anaesthetic levels at arrest for all 24 pigs were not significantly 
different (86.8µg/ml for bupivacaine and I07.9µg/ml for ropivacaine). The arrest levels 
for survivors and non-survivors were also not significantly different (90.1 µg/ml 
compared to 104.6µg/ml) . 
It seems therefore, that in pigs that survived, survival was due to redistribution of local 
anaesthetic resulting in rapidly falling plasma concentrations, which would enable the 
myocardial concentration of local anaesthetic to decrease, and that within the 15 minute 
study period, those pigs that achieved sufficient redistribution were the pigs that 
survived. This has implications for the treatment of local anaesthetic induced cardiac 
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arrest, in that resuscitation should continue for a prolonged period to allow for drug 
redistribution away from the heart. 
The mortality in the ropivacaine treated pigs was substantially different in Experiment 
1 compared to Experiment 2 (16% versus 50%). The initial result was the expected 
result, and it was surprising to note the substantially worse mortality in Experiment 2. 
However, the higher survival rate in Experiment 1 is felt to be due purely to chance, a 
consequence of the small numbers of pigs studied. 
When taken as one large group of 24 pigs, the rate of survival between the pigs treated 
with ropivacaine was 67% compared to 50% for the bupivacaine treated pigs. This 
difference does not reach statistical significance. In order to show statistical 
significance, power analysis shows that a total of 56 pigs would need to be studied. 
However, the clinical relevance of a 67% survival compared to a 50% survival is 
questionable, as both rates are extremely poor. Local anaesthetic toxicity should be 
avoided. 
The conclusion to be drawn from this study is that a statistically significant difference 
in the mortality due to overdose of ropivacaine or bupivacaine has not been shown. 
The mortality from cardiac arrest induced by local anaesthetic overdose is extremely 
high. Most evidence concerning cardiac toxicity of local anaesthetics however suggests 
that ropivacaine is less likely than bupivacaine to cause cardiac arrest. 
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